Synlogic Inc (SYBX) USD0.001
Sell:$1.21Buy:$1.29
$0.03
(2.38%)
- This stock can be held in a
Stocks and Shares ISA$0.03
(2.38%)$0.03
(2.38%)Company Information
About this company
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Key people
Key facts
- EPICSYBX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS87166L2097
- Market cap$15.38m
- Employees1
- Shares in issue11.98m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.